TEANECK, N.J. - Cognizant Technology Solutions Corp. (NASDAQ:CTSH) has announced a collaboration with NVIDIA Corporation (NASDAQ:NVDA) to enhance drug discovery in the life sciences sector using NVIDIA's BioNeMo generative AI platform. This initiative aims to improve the productivity of the drug development process and accelerate the introduction of new treatments to the market.
Generative AI technologies are transforming the traditional drug discovery process, which typically involves analyzing large volumes of scientific literature and clinical data. By using generative AI, clinical researchers can quickly process these datasets, more accurately predict drug compound interactions, and identify new drug development pathways.
Anna Elango, Executive Vice President at Cognizant, emphasized the transformative potential of generative AI in drug research and development, stating that it could make the creation of life-saving treatments faster, smarter, and more widely accessible.
The partnership with NVIDIA will allow Cognizant to offer life sciences clients a range of model-making services, including pre-trained models, frameworks, and APIs, to train and customize enterprise models using proprietary data with minimal manual data analysis and coding.
Alvin DaCosta, Vice President at NVIDIA, highlighted generative AI's role in driving enterprise productivity gains. He noted that Cognizant's use of NVIDIA BioNeMo will provide secure and reliable AI services for custom drug discovery applications.
Cognizant works with global firms across the pharmaceutical, biotech, and medical device sectors, enhancing science, improving patient outcomes, and increasing business value. The company supports more than 120 global manufacturing lines and aids over 18 million patients with medical device company products.
Looking beyond healthcare, Cognizant plans to explore additional applications of generative AI in manufacturing and automotive engineering in collaboration with NVIDIA. The company also intends to establish an NVIDIA AI Center of Excellence to innovate with NVIDIA technologies, including Metropolis, Omniverse, and the AI Enterprise platforms, benefiting clients across various industries.
This announcement is based on a press release statement from Cognizant.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.